Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 14;16(16):2842.
doi: 10.3390/cancers16162842.

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

Luca Bertolaccini  1 , Monica Casiraghi  1   2 , Claudia Bardoni  1 , Cristina Diotti  1 , Matteo Chiari  1 , Antonio Mazzella  1 , Filippo de Marinis  3 , Lorenzo Spaggiari  1   2
Affiliations

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens

Luca Bertolaccini et al. Cancers (Basel). .

Abstract

Non-small cell lung cancer (NSCLC) poses a significant challenge in clinical oncology, necessitating continual refinement of treatment approaches in stages II and III. Recent advancements have highlighted the potential of neoadjuvant therapy in optimising patient outcomes. Biomarker testing guides neoadjuvant therapy decisions, including epidermal growth factor receptor (EGFR) mutation and programmed death-ligand 1 (PD-L1) expression testing. Neoadjuvant therapy aims to improve oncological outcomes by treating micrometastatic disease and assessing tumour response before surgery. Disease-free survival is a surrogate endpoint for overall survival in both neoadjuvant and adjuvant settings. Multidisciplinary collaboration is crucial for individualised treatment planning and optimising patient care. The management of NSCLC requires a comprehensive approach, integrating expertise across disciplines and tailoring treatment strategies to individual patient needs. Neoadjuvant therapy shows promise in improving long-term outcomes, with biomarker testing guiding treatment decisions. Challenges such as defining borderline resectability and differentiating pseudoprogression highlight the need for ongoing research and collaboration.

Keywords: lung cancer; management; neoadjuvant treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Batra U., Prabhash K., Agarwal J.P., Darlong L., Munshi A., Penumadu P., Thangakunam B., Bansal A. Clinical management of stage III non-small cell lung cancer in India: An expert consensus statement. Asia Pac. J. Clin. Oncol. 2023;19:606–617. doi: 10.1111/ajco.13938. - DOI - PubMed
    1. John A.O., Ramnath N. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. Oncologist. 2023;28:752–764. doi: 10.1093/oncolo/oyad125. - DOI - PMC - PubMed
    1. Mountzios G., Remon J., Hendriks L.E.L., Garcia-Campelo R., Rolfo C., Van Schil P., Forde P.M., Besse B., Subbiah V., Reck M., et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer—Opportunities and challenges. Nat. Rev. Clin. Oncol. 2023;20:664–677. doi: 10.1038/s41571-023-00794-7. - DOI - PubMed
    1. Guarize J., Spaggiari L., Bertolaccini L. In EBUS Signo Vinces: New Indications in Thoracic Oncology for Mediastinal Lymph Node Staging Using Endobronchial Ultrasound. Front. Oncol. 2022;12:934986. doi: 10.3389/fonc.2022.934986. - DOI - PMC - PubMed
    1. Guarize J., Diotti C., Casiraghi M., Donghi S., Di Tonno C., Mancuso P., Zorzino L., Sedda G., Radice D., Bertolaccini L., et al. Diagnostic Performance and Cell Count of EBUS-TBNA Needle Gauges: A Prospective Trial. J. Clin. Med. 2023;12:4033. doi: 10.3390/jcm12124033. - DOI - PMC - PubMed